Byondis Appoints Scientific Advisory Board of ADC and Oncology Development Specialists

As the antibody-drug conjugate pipeline expands across the industry, Byondis B.V. has formalized external scientific oversight by establishing a Scientific Advisory Board composed of specialists in ADC chemistry, early-phase clinical design, and targeted oncology therapeutics. The move signals a deliberate effort to stress-test the company's proprietary platform technologies against established regulatory and scientific benchmarks before advancing candidates further into the clinic.

The board draws on credentials directly relevant to ADC development complexity. Dr. John Lambert, former Chief Scientific Officer at ImmunoGen, contributed to the foundational science behind Kadcyla (trastuzumab emtansine) and Elahere (mirvetuximab soravtansine), two approvals that set the precedent for ADC GMP frameworks and conjugation process validation now referenced across the industry. His three decades of linker-payload chemistry experience carries direct relevance to the manufacturing and quality systems challenges that define ADC programs today.

Dr. Anthony Tolcher brings first-in-human trial design expertise, having served as principal investigator on studies that led to FDA approval of trastuzumab emtansine, pembrolizumab, durvalumab, and cemiplimab. For regulatory affairs leads tracking IND-enabling work and Phase I protocol design, his involvement adds a layer of early-phase rigor to Byondis' clinical advancement strategy. Dr. Kapil Dhingra, founder of KAPital Consulting and former Head of Oncology Clinical Development at Hoffmann-La Roche, contributes strategic development experience spanning ADC and targeted therapeutic programs across multiple geographies.

The advisory board's formation reflects a broader industry dynamic: ADC programs impose manufacturing demands that differ materially from conventional biologics. Conjugation operations require contained, purpose-built GMP suites; linker-payload combinations introduce potent compound handling requirements under 21 CFR Part 211 and applicable ICH Q10 quality system expectations. Companies scaling ADC pipelines without corresponding investment in specialized facility design and process validation risk compressing timelines at the CMC stage, where regulatory scrutiny on sterility assurance and analytical characterization is highest.

Byondis, based in Nijmegen, operates its own ADC manufacturing infrastructure, positioning the advisory board's scientific input as directly applicable to both pipeline progression and the underlying platform technologies the company is developing. The depth of ADC-specific expertise assembled suggests the advisory function will extend beyond clinical strategy into the technical and quality dimensions that determine regulatory readiness.

How Byondis translates advisory input into documented process validation and CMC package development will be a measurable indicator of the board's operational impact as the pipeline advances toward pivotal-stage milestones.

Source: Byondis B.V. via GlobeNewswire, 18 May 2026.